Novel agent for treatment of Parkinson's disease in clinical development

15-Nov-2007

Lundbeck has initiated phase I clinical trials with the pharmaceutical candidate Lu AA47070 to investigate safety, tolerability and the pharmacokinetic profile of the compound in humans. Lu AA47070 is a novel adenosine receptor antagonist that has been shown to be efficacious in a number of animal models for neurological diseases including models of Parkinson's disease. It is therefore expected that Lu AA47070 may have a potential in certain neurological indications and could be an alternative to e.g. dopamine agonists in the treatment of Parkinson's disease.

"Lu AA47070 is a very promising compound with a unique profile and has the potential to make a significant difference to for instance patients suffering from Parkinson's disease," says Peter Høngaard Andersen, Head of Research at Lundbeck. He continues: "Lu AA47070 is discovered at Lundbeck and is our first compound within the neurology area from our internal research.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances